KLF8 Antibody

Basic Research Questions

• What is KLF8 and why is it significant in cancer research?

KLF8 is a transcription factor containing a zinc finger DNA-binding domain typical for the KLF family and weighs approximately 38 kDa . It functions as both a transcriptional repressor and activator, binding to CACCC-box promoter elements and the GT-box of cyclin D1 promoter . KLF8 is expressed in several tissues with significant presence in kidney, lung, and liver .

KLF8 has emerged as a critical player in cancer research due to its roles in:

• Mediating cell cycle progression at G1 phase as a downstream target of focal adhesion kinase (FAK)

• Promoting oncogenic transformation and epithelial-to-mesenchymal transition

• Enhancing cell proliferation, invasion, and metastasis

• Facilitating DNA repair mechanisms affecting therapeutic resistance

• What experimental applications are best suited for KLF8 antibodies?

KLF8 antibodies are utilized in multiple research applications:

Selection depends on specific research questions - WB for expression comparison, IHC for tissue pattern analysis, IF for localization studies, and ChIP/EMSA for transcriptional function investigations .

• How to select between polyclonal and monoclonal KLF8 antibodies for different research applications?

The choice between polyclonal and monoclonal KLF8 antibodies depends on experimental requirements:

Polyclonal KLF8 antibodies:

• Recognize multiple epitopes on KLF8

• Generally provide higher sensitivity

• Advantageous when protein abundance is low

• Ideal for applications like IP and ChIP

• Example: Rabbit polyclonal antibody against KLF8 Middle Region (ABIN2777635) with reactivity across multiple species

Monoclonal KLF8 antibodies:

• Target a single epitope with high specificity

• Provide consistent results between experiments

• Preferable for quantitative and reproducible applications

• Better for distinguishing between closely related proteins

• Example: Mouse monoclonal antibody 2E10 targeting amino acids 1-98 of KLF8

Application-specific recommendations:

• For Western Blotting: Both types work well; monoclonal for reproducibility, polyclonal for detection of low abundance KLF8

• For ChIP: Polyclonal antibodies often perform better

• For Immunohistochemistry: Consider tissue fixation effects on epitope availability with both types

• For multiplexed assays: Monoclonal antibodies may provide better specificity

When studying KLF8's role in DNA repair, polyclonal antibodies may detect multiple modified forms, while phospho-specific monoclonal antibodies can track specific modification states .

• What are effective validation strategies to confirm KLF8 antibody specificity?

Rigorous validation is essential for reliable KLF8 detection:

Essential validation approaches:

• Genetic knockdown/knockout controls:

  • Compare antibody signal in KLF8-depleted vs. control samples

  • Example: 231-K8ikd cells with Tet-on inducible shRNA against KLF8 showed reduced signal upon induction

• Cell line controls with known expression levels:

  • MDA-MB-231 cells express high KLF8 levels

  • MCF-10A cells express little or no endogenous KLF8

  • Western blotting of these lines confirms antibody specificity

• Molecular weight verification:

  • Confirm detection at expected molecular weight (~38 kDa)

  • Account for post-translational modifications that may alter migration

• Supershift assays for DNA-binding studies:

  • EMSA with anti-KLF8 antibody demonstrates specificity

  • Example: In Klf1-ER induction studies, a band could be supershifted by anti-Klf8 antibody but not by anti-Klf3 antibody

• Recombinant protein testing:

  • Use purified recombinant KLF8 as positive control

  • Example: GST-mKlf8 fusion protein expressed in bacteria and purified on glutathione beads

• Multiple antibody validation:

  • Use antibodies targeting different KLF8 regions to confirm findings

  • Example: Comparing results between Middle Region antibody and N-Term antibody

For functional research, antibody validation should include experimental confirmation that the detected protein exhibits expected biological activities, such as DNA binding or transcriptional regulation .

• How do sample preparation methods affect KLF8 detection quality?

Optimal sample preparation is crucial for reliable KLF8 detection:

For Western Blotting:

• Use RIPA buffer with protease inhibitors for extraction

• Add phosphatase inhibitors if studying phosphorylated KLF8

• Nuclear extraction may concentrate KLF8 (primarily nuclear)

• Standardize protein loading (20-50 μg recommended)

• Sonication helps shear DNA and release chromatin-bound KLF8

For Immunohistochemistry:

• Fixation affects epitope availability: 10% neutral buffered formalin is standard

• Antigen retrieval optimization critical: citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

• Fresh frozen sections may preserve certain epitopes better than FFPE

For Immunofluorescence:

• PFA fixation (4%) followed by Triton X-100 permeabilization (0.1-0.5%)

• Example: RT4 cells successfully stained using 4 μg/ml of ab221867

Timing considerations:

• KLF8 expression and modification can be induced by various stimuli

• For DNA damage response studies, collect samples 4-8 hours after doxorubicin treatment to capture phosphorylation changes

• For EMT studies, TGF-β1 induces KLF8 in a dose-dependent manner

Cell fractionation for mechanistic studies:
When investigating KLF8's dual nuclear/cytoplasmic functions, subcellular fractionation protocols can separate pools of KLF8 with different modifications and binding partners .

Advanced Research Questions

• How do post-translational modifications of KLF8 influence antibody detection and selection?

KLF8 undergoes multiple post-translational modifications that significantly impact antibody recognition:

Phosphorylation:

• DNA-PKcs phosphorylates KLF8 at Ser-80 in response to DNA damage

• Phospho-specific antibodies required for studying this modification

• Antibodies raised against regions containing phosphorylation sites may show altered binding to phosphorylated forms

SUMOylation:

• SUMOylation by PIAS E3 ligases occurs following phosphorylation

• Adds ~12 kDa to protein size, creating higher molecular weight bands

• May mask epitopes or alter protein conformation affecting antibody binding

PARylation:

• PARP-1 catalyzes poly(ADP-ribosyl)ation of KLF8

• Creates heterogeneous high molecular weight smears in Western blots

• Significantly alters apparent molecular weight

Sequential modification pathway:
Research has established that in response to DNA damage, KLF8 undergoes:

• Phosphorylation by DNA-PKcs

• SUMOylation by PIASs
  These modifications depend on interactions with DNA-PKcs, PIASs, and PARP-1 .

Recommended approaches:

• Use phosphatase or SUMO protease treatments as controls

• Select antibodies targeting regions unlikely to be modified

• Use multiple antibodies targeting different epitopes

• Consider the biological context and likely modification states in your experimental system

Notably, interactions with PARP-1 are critical for KLF8's DNA repair functions as shown in studies using the PARP-1 binding-defective KLF8 mutant ZF1,2mCs .

• What are optimal experimental designs for investigating KLF8's role in DNA damage response?

Research has established KLF8 as a key player in DNA repair. The following experimental designs are recommended:

DNA Damage Induction and Response Assessment:

Mechanistic Investigation:

• KLF8 Localization:

  • Track KLF8 recruitment to DNA damage sites using IF

  • Co-stain with γH2A.X to identify damage foci

• Protein Interaction Studies:

  • Co-IP KLF8 with PARP-1, DNA-PKcs, and PIASs

  • Use cells with/without DNA damage induction

  • Include DNase treatment controls

• Modification Cascades:

  • Examine phosphorylation state using phospho-serine antibodies

  • Study SUMOylation patterns with SUMO-specific antibodies

  • Use mutants (e.g., S80A, K67R) to disrupt modification sites

Functional Research Example:
In breast cancer studies, researchers demonstrated that:

• KLF8 expression inversely correlated with doxorubicin-induced DNA damage

• When KLF8 was knocked down, cells showed increased sensitivity to doxorubicin

• KLF8 reduces DNA damage levels in PARP-1+/+ but not PARP-1-/- cells

• KLF8 function requires interaction with catalytically active PARP-1

These approaches showed that KLF8 promotes DNA repair rather than preventing damage, providing potential therapeutic targets for chemosensitizing therapy .

• What specialized techniques enable detection of low-abundance KLF8 in normal tissues versus cancer tissues?

KLF8 is barely detectable in normal tissues but aberrantly overexpressed in cancers, requiring specialized detection approaches:

Signal Amplification Strategies:

• Tyramide signal amplification (TSA) for IHC/IF increases sensitivity 10-100 fold

• Polymer-based detection systems offer superior sensitivity over standard ABC methods

• For Western blots, highly sensitive chemiluminescent substrates (femtogram detection limits)

• Consider Li-COR infrared detection for quantitative comparison across wide dynamic range

Sample Enrichment Methods:

• Nuclear extraction concentrates KLF8 (primarily a nuclear protein)

• Immunoprecipitation before Western blotting (IP-Western) for low-expressing samples

• Increase protein loading for Western blots (50-100 μg for normal tissue samples)

Antibody Optimization for Low Expression:

• Extended primary antibody incubation (overnight at 4°C)

• Higher antibody concentration for normal tissues than cancer samples

• Reduced washing stringency to preserve weak signals

• Titration experiments to determine optimal conditions

Comparative Analysis Protocol:
When comparing normal and cancer tissues:

• Process all samples simultaneously under identical conditions

• Include gradient standards for quantitative comparison

• Use digital pathology quantification tools

• Employ slide-scanning technology with consistent exposure settings

Research Validation:
Studies showed KLF8 protein staining in:

• 92.65% of high-grade prostate cancer

• 66.15% of low-grade prostate cancer

• Only 6.82% of adjacent normal tissues

This dramatic difference highlights the need for detection methods optimized for both high and low expression ranges when comparing cancer and normal tissues.

• How can KLF8 antibodies be effectively employed in chromatin immunoprecipitation (ChIP) studies?

ChIP assays with KLF8 antibodies require careful optimization for successful identification of KLF8 target genes:

Antibody Selection for ChIP:

• Choose antibodies validated specifically for ChIP applications

• Polyclonal antibodies targeting non-DNA-binding domains often perform better

• Consider epitope location relative to DNA-binding zinc finger domains

• Verify ChIP-grade quality through preliminary testing

Cross-linking Optimization:

• Standard protocol: 1% formaldehyde for 10 minutes at room temperature

• For studying KLF8 co-factors: dual cross-linking with DSG followed by formaldehyde

• Cross-linking time affects recovery: optimize for each cell type

• Quench with 125 mM glycine for precisely 5 minutes

Chromatin Preparation:

• Target fragment size: 200-500 bp for standard ChIP, 100-300 bp for ChIP-seq

• Sonication conditions require optimization for each cell type

• Verify fragmentation by agarose gel electrophoresis

• Pre-clear chromatin with protein A/G beads to reduce background

Controls and Validation:

• IgG negative control (same species as KLF8 antibody)

• Input DNA (typically 5-10% of starting material)

• Positive control loci (known KLF8 targets):

  • Cyclin D1 promoter GT-box

  • E-cadherin promoter

  • MMP9 promoter

  • FHL2 promoter GT-box

Research Application Example:
Researchers demonstrated that KLF8 directly binds to and activates the FHL2 gene promoter:

• Used promoter reporter assays to identify responsive regions

• Performed ChIP assays to confirm direct binding to the GT-box

• Validated through functional assays showing that siRNA-mediated repression of FHL2 in KLF8-overexpressing cells reversed EMT and metastatic phenotypes

This approach established the KLF8-FHL2 pathway as a critical signaling mechanism underlying cancer invasion and metastasis .

• What methodological approaches are most effective for studying KLF8's role in epithelial-to-mesenchymal transition (EMT)?

KLF8 is a critical regulator of EMT. The following methodological approaches are recommended:

Expression Analysis in EMT Models:

Functional Assays:

• Migration Analysis:

  • Wound-healing assays showed KLF8 overexpression accelerated cell migration by ~400%

  • Transwell migration assays quantified increased motility

• Invasion Assessment:

  • Matrigel-coated transwell assays demonstrated KLF8 overexpression increased LoVo cell invasion by 415.0%

  • Correlated with EMT marker changes

• Induction Studies:

  • TGF-β1 induced KLF8 in a dose-dependent manner

  • Blocking with neutralizing antibodies suppressed endogenous KLF8 expression

  • Demonstrated KLF8 as a mediator of TGF-β1-induced EMT

Molecular Mechanism Investigation:

• Promoter Analysis:

  • ChIP assays showed KLF8 directly binds FHL2 promoter

  • Reporter assays confirmed functional activation

• Knockdown Validation:

  • siRNA-mediated FHL2 repression in KLF8-overexpressing cells reversed EMT phenotypes

  • Established FHL2 as critical downstream effector

In Vivo Validation:

• Orthotopic implantation of KLF8-overexpressing cells showed increased tumor volume

• FHL2 knockdown inhibited KLF8-mediated proliferation and metastasis

• IHC of serial sections confirmed KLF8/FHL2 co-expression in metastatic tissues

This comprehensive approach established KLF8-induced FHL2 activation as a novel signaling mechanism underlying cancer invasion and metastasis, demonstrating effective use of KLF8 antibodies throughout the research pipeline .

• How do different fixation and antigen retrieval methods affect KLF8 epitope availability in immunohistochemistry?

Fixation and antigen retrieval significantly impact KLF8 detection in tissues:

Fixation Method Comparison:

Antigen Retrieval Optimization:

• Heat-Induced Epitope Retrieval (HIER):

  • Citrate buffer (pH 6.0): Standard starting point for KLF8

  • EDTA buffer (pH 9.0): May work better for some KLF8 epitopes

  • Tris-EDTA (pH 9.0): Alternative for heavily modified KLF8

• Retrieval Methods:

  • Pressure cooker (high temperature, short time): Often most effective

  • Microwave: Variable results depending on equipment

  • Water bath (lower temperature, longer time): Gentler but less efficient

• Protocol Modifications:

  • Extended retrieval time for heavily fixed samples

  • Multiple retrieval cycles for difficult tissues

  • Fresh frozen sections may eliminate need for retrieval

Research Application Examples:

• PFA-fixed, Triton X-100 permeabilized RT4 cells were successfully stained for KLF8 using ab221867 at 4 μg/ml in ICC/IF

• KLF8 immunohistochemical staining performed on prostate cancer samples revealed expression in 92.65% of high-grade PCa versus only 6.82% of adjacent normal tissues

Recommendation for Comparative Studies:
When comparing normal and cancer tissues, identical fixation and retrieval conditions are essential. Consider testing multiple antibodies targeting different KLF8 epitopes to ensure comprehensive detection across different fixation conditions.

• What are effective strategies for investigating KLF8 protein interactions in the context of cancer progression?

KLF8 functions through complex protein interaction networks that can be studied using these approaches:

Co-Immunoprecipitation Strategies:

Studying DNA Repair Protein Interactions:
Research has demonstrated KLF8 interactions with key DNA repair proteins:

• PARP-1 Interaction:

  • Wild-type KLF8 attenuated γH2A.X levels in doxorubicin-treated PARP-1+/+ cells

  • PARP-1-binding-defective KLF8 mutant (ZF1,2mCs) failed to do so

  • KLF8-induced decrease in DNA damage required catalytically active PARP-1

• DNA-PKcs Interaction:

  • KLF8 phosphorylation increased in response to doxorubicin treatment

  • This modification by DNA-PKcs was necessary for subsequent SUMOylation

  • Required for KLF8's DNA repair functions

• PIAS E3 Ligases:

  • Mediate SUMOylation of KLF8 following phosphorylation

  • Part of a sequential modification cascade in DNA damage response

Advanced Techniques:

• Proximity Ligation Assay (PLA): Visualizes protein interactions in situ

• FRET/BRET Analysis: Measures real-time protein interactions in living cells

• BiFC (Bimolecular Fluorescence Complementation): Visualizes protein interactions in living cells

• Sequential ChIP (Re-ChIP): Identifies co-occupation of promoters

Functional Validation:

• Express wild-type versus interaction-deficient mutants (e.g., ZF1,2mCs, S80A, K67R)

• Assess impact on downstream processes (DNA repair, EMT, proliferation)

• Correlate with clinical outcomes in patient samples

These approaches have established that KLF8 interactions with PARP-1, DNA-PKcs, and PIASs are critical for its role in promoting DNA repair and therapeutic resistance in breast cancer cells .

• How does KLF8 knockout/knockdown methodology affect experimental interpretation in cancer biology?

KLF8 manipulation strategies have distinct impacts on experimental outcomes and interpretation:

Comparison of KLF8 Manipulation Techniques:

Experimental Design Considerations:

• Knockdown Verification:

  • Confirm at both mRNA and protein levels

  • Quantify knockdown efficiency (typically >70% required)

  • Monitor stability over experimental duration

• Rescue Experiments:

  • Re-express wild-type or mutant KLF8 to confirm specificity

  • Example: KLF8 overexpression progressed to a 4-fold increase in cancer area 35 days after injection

• Phenotypic Analysis:

  • Cell proliferation (WST-1, clonogenic assays)

  • Cell cycle analysis (G0/G1-phase arrest observed with KLF8 knockdown)

  • Invasion assays (KLF8 knockdown suppressed invasion)

  • DNA damage assessment (Comet assays, γH2A.X)

Research Applications:

• In breast cancer studies: KLF8 knockdown increased sensitivity to doxorubicin-induced DNA damage and cell death

• In osteosarcoma: Lentivirus-mediated KLF8 siRNA inhibited growth and invasion

• In colorectal cancer: KLF8 knockdown reversed EMT and metastatic phenotypes

Enhanced Experimental Approaches:

• Use multiple knockdown/knockout strategies to confirm results

• Include rescue experiments with wild-type and mutant KLF8

• Employ inducible systems to study temporal requirements

• Combine with patient-derived models for clinical relevance